Oncotelic Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Oncotelic Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $70.0K | Apr 15, 2025 |
| FY2021 | Dec 31, 2020 | $1.74M | Apr 15, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $1.74M | Apr 15, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2013 | $95.0K | Mar 30, 2015 |
| FY2014 | Dec 31, 2012 | $156.0K | Mar 30, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $249.28M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.52M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($7.90M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $5.09M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($9.39M) | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | ($9.50M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($6.64M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($712.7K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($13.81M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($13.65M) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.19M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($3.58M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($6.65M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($9.72M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($9.13M) | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | ($7.58M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($4.31M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($712.7K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($13.84M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($13.76M) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.4K | Apr 15, 2026 |
| FY2023 | Dec 31, 2023 | $61.1K | Apr 12, 2024 |
| FY2023 | Dec 31, 2022 | $756.9K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $3.66M | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | $4.30M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.37M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $649.8K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $10.47M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $8.76M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $9.09M | Mar 30, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.38M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($740.3K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($1.32M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.45M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($4.43M) | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | ($2.81M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($2.28M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($241.0K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($10.93M) | Apr 10, 2019 |
| FY2013 | Dec 31, 2013 | ($7.00M) | Mar 20, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $13.0K | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $17.0K | Mar 25, 2016 |
| FY2011 | Dec 31, 2009 | $109.0K | Mar 28, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $393.09M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $26.68M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $30.01M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $36.12M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $23.61M | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | $23.66M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $23.68M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.75M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.17M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $14.11M | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $131.36M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $19.20M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $18.40M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $16.92M | Apr 12, 2024 |
| FY2011 | Dec 31, 2011 | $2.26M | Mar 28, 2012 |
| FY2011 | Dec 31, 2010 | $10.82M | Mar 28, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.76M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $8.25M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $12.13M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $19.41M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $7.96M | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | $11.77M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $16.90M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.46M | May 14, 2020 |
| FY2019 | Dec 31, 2017 | ($483.6K) | May 14, 2020 |
| FY2018 | Dec 31, 2016 | $12.50M | Apr 10, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.79M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.79M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $5.99M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $12.07M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $21.06M | Apr 12, 2024 |
| FY2022 | Dec 31, 2020 | $21.06M | Apr 20, 2023 |
| FY2020 | Dec 31, 2019 | $21.06M | Apr 15, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $211.24M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($38.04M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($33.52M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($25.93M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($31.02M) | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | ($21.63M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($12.13M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($5.49M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($292.28M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($278.46M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $170.4K | Apr 12, 2024 |
| FY2023 | Dec 31, 2022 | $241.5K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $568.8K | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | $474.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $82.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.5K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.12M | Apr 10, 2019 |
| FY2018 | Dec 31, 2016 | $3.54M | Apr 10, 2019 |
| FY2017 | Dec 31, 2015 | $27.29M | Apr 17, 2018 |
| FY2016 | Dec 31, 2014 | $30.03M | Mar 30, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Apr 12, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 20, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 442.60M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 407.29M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 399.18M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 391.85M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 375.29M | Apr 20, 2023 |
| FY2021 | Dec 31, 2020 | 90.60M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 84.07M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 6.84M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 26.55M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | 26.55M | Apr 17, 2018 |